IVD SECTOR QUARTERLIES ROUND-UP: Spending spree puts Inverness in red for Q4
This article was originally published in Clinica
Executive Summary
Charges resulting from a busy year of acquisition and integration activities have led to Inverness Medical Systems posting a net loss for the fourth quarter of 2007. The Waltham, Massachusetts-based diagnostics specialist recorded a deficit of $12.5m, a significant drop compared to the profit of $6m it made over the same period in 2006. Inverness' fourth-quarter net revenue rose by 83% to approximately $288m, largely helped by contributions from acquired businesses which boosted sales of the company's professional diagnostics products. This core business segment generated $234.2m in revenue ($139.3m derived from acquired product lines), a sharp rise compared to the same period in 2006, during which it made $87.2m.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.